Department of Urology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX, 77030, USA.
Due to the relatively heterogeneous metastatic spread of renal cell carcinoma (RCC) through both hematogenous and lymphatogenous routes, the surgical extirpation of regional lymph nodes in the treatment of RCC has long been a controversial topic. Individual risk is dependent on multiple variables including tumor stage, grade, and histologic sub-type, in addition to many others. Controversy exists over whether lymph node dissection (LND) simply provides improved staging or whether removal of pathologic nodes offers a therapeutic advantage. Herein, we evaluate the available data regarding the use of LND in the treatment of RCC. While we believe that LND may provide an opportunity for cure in a select group of patients, there are many variables to consider when determining its applicability to an individual patient.
Written by:
Chapin BF, Delacroix SE Jr, Wood CG. Are you the author?
Reference: Int J Clin Oncol. 2011 Apr 28. Epub ahead of print.
doi: 10.1007/s10147-011-0241-3
PubMed Abstract
PMID: 21523561
UroToday.com Renal Cancer Section
